KRAS and neoplasm: Blocking zDHHC20-mediated EGFR S-acylation has also been shown to reduce PI3K signaling and MYC levels and suppress cell growth in vitro and tumor growth in an in vivo model of KRAS-mutant lung adenocarcinoma (75).